Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710051 | 0.95 | MEN1 (0.40) | GRIK1MEN1KMT2APARP14NSD2 | |
| SCHEMBL6711425 | 0.92 | PARP14 (0.40) | GRIK1MEN1KMT2APARP14NSD2 | |
| SCHEMBL6710077 | 0.92 | CASP3 (0.38) | GRIK1MEN1KMT2A | |
| SCHEMBL6707655 | 0.92 | GRIK1 (0.45) | GRIK1MEN1KMT2APARP14 | |
| SCHEMBL6713651 | 0.92 | MEN1 (0.44) | GRIK1MEN1KMT2AEGLN1NR1H4 | |
| SCHEMBL6713931 | 0.91 | GRIK1 (0.41) | GRIK1MEN1KMT2ANSD2NR1H4 | |
| SCHEMBL6708772 | 0.91 | PARP14 (0.42) | GRIK1MEN1KMT2APARP14NR1H4 | |
| SCHEMBL6711736 | 0.90 | GPR35 (0.38) | GRIK1PARP14NR1H4PPARGPPARD | |
| SCHEMBL6709043 | 0.90 | GRIK1 (0.37) | GRIK1MEN1KMT2ANR1H4PPARG | |
| SCHEMBL6708829 | 0.89 | PARP14 (0.42) | MEN1KMT2APARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GRIK1 3885/4885MEN1 4100/4885KMT2A 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.